EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide

Naveed Sattar, Bruno Linetzky, Giacomo Ruotolo, Subodh Verma, Harald Sourij, Hui Wang, Kadie Vanderman, Jonathan M Wilson, Ryan M Griffin, Adam Stefanski, Paul M Ridker

JACC · 2026-08 · 88 (6) · 652-666

DOI: 10.1016/j.jacc.2026.04.044 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JACC, 2026-08. Verfasst von Naveed Sattar und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Obesity, Tirzepatide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesObesityTirzepatideFemaleHumansMaleMiddle AgedBiomarkersDiabetes Mellitus, Type 2Double-Blind MethodHeart Disease Risk FactorsTime Factors

Stichwörter der Autor:innen

endothelial dysfunctioninflammationmetabolic/adiposity/hepatic stressthrombosistirzepatide

Substanzen

BiomarkersTirzepatide

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Eli Lilly and Company, Indianapolis, Indiana, USA. Electronic address: linetzky_bruno@lilly.com.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
  • Cardiometabolic Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • TechData Service Company, LLC, King of Prussia, Pennsylvania, USA.

Förderung

  • Eli Lilly and Company
  • American Heart Association

Zitieren

APA

Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., & Ridker, P. M. (2026). Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide. JACC, 88(6), 652-666. https://doi.org/10.1016/j.jacc.2026.04.044

Vancouver

Sattar N, Linetzky B, Ruotolo G, Verma S, Sourij H, Wang H, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide. JACC. 2026;88(6):652-666. doi:10.1016/j.jacc.2026.04.044

BibTeX
@article{Sattar2026,
  author = {Sattar, Naveed and Linetzky, Bruno and Ruotolo, Giacomo and Verma, Subodh and Sourij, Harald and Wang, Hui and Vanderman, Kadie and Wilson, Jonathan M and Griffin, Ryan M and Stefanski, Adam and Ridker, Paul M},
  title = {Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {6},
  pages = {652--666},
  doi = {10.1016/j.jacc.2026.04.044}
}
Kostenlos starten →